License and Collaboration Agreements	9 Months Ended
Sep. 30, 2022
License And Collaboration Agreements [Abstract]
License and Collaboration Agreements	(6) License and Collaboration Agreements For the nine months ended September 30, 2022, the Company recorded $0.5 million relating to the collaboration agreement with Adimab and $0.2 million relating to the license agreement (the "MIT License Agreement") with the Massachusetts Institute of Technology ("MIT") through Cullinan Amber Corp. ("Cullinan Amber") within research and development expenses. For the three months ended September 30, 2022, the company recorded less than $0.1 million relating to license and collaboration agreements. For the nine months ended September 30, 2021, the Company recorded $3.0 million under a revenue sharing agreement with Taiho upon receipt of an upfront payment for licensing the Greater China rights for zipalertinib (CLN-081/TAS6417) to Zai Lab (Shanghai) Co., Ltd. and $0.1 million relating to the MIT License Agreement. For the three months ended September 30, 2021, the company recorded less than $0.1 million relating to license and collaboration agreements.

License and Collaboration Agreements

9 Months Ended

Sep. 30, 2022

License And Collaboration Agreements [Abstract]

(6)

License and Collaboration Agreements

For the nine months ended September 30, 2022, the Company recorded $0.5 million relating to the collaboration agreement with Adimab and $0.2 million relating to the license agreement (the "MIT License Agreement") with the Massachusetts Institute of Technology ("MIT") through Cullinan Amber Corp. ("Cullinan Amber") within research and development expenses. For the three months ended September 30, 2022, the company recorded less than $0.1 million relating to license and collaboration agreements.

For the nine months ended September 30, 2021, the Company recorded $3.0 million under a revenue sharing agreement with Taiho upon receipt of an upfront payment for licensing the Greater China rights for zipalertinib (CLN-081/TAS6417) to Zai Lab (Shanghai) Co., Ltd. and $0.1 million relating to the MIT License Agreement. For the three months ended September 30, 2021, the company recorded less than $0.1 million relating to license and collaboration agreements.